Please Wait...

Study Points Way to Increased Efficacy in Respiratory Syncytial Virus Vaccine

Respiratory syncytial virus (RSV) is increasingly being recognized as an important cause of disease in older adults worldwide. Its impact is estimated to be comparable to or even greater than that of influenza. However, RSV is not typically tested for, as there is no specific treatment. A successful vaccine would represent a vital breakthrough, deeply benefiting this growing segment of the population.

To that end, a double-blind phase 1 study was conducted with subjects 60 years of age and older. The subjects received vaccines containing escalating doses of soluble RSV fusion protein(sF) alone or adjuvanted with glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). The full report of the study with its conclusions can be read in here.

One of the authors of this key study is Craig Curtis, MD, CPI, and Chief Medical Officer at Bioclinica. Dr. Curtis is a Florida-licensed physician with Board Certification in Family Medicine. He has over 15 years of clinical trial experience covering all phases of research and numerous therapeutic areas. He has served as Principal Investigator on over 200 trials in the areas of general medicine, psychiatry, neurology, analgesia, and early clinical development.

Dr. Curtis is a member of the Association of Clinical Research Professionals (ACRP), the Drug Information Association (DIA), and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He earned his medical degree from Northeastern Ohio University College of Medicine.

Read the study now:
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-likereceptor-4 agonist and stable emulsion adjuvant

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (12 hours ago)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (17 hours ago)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (17 hours ago)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (19 hours ago)
Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will… https://t.co/BX6wzXctMm
bioclinica (3 days ago)
Let's talk oncology clinical trials at #ESMO18 ! Tap the knowledge of medical & scientific experts @bioclinica who'… https://t.co/RlTjGND5Qg
bioclinica (4 days ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner